M
Michael Altenbuchinger
Researcher at University of Regensburg
Publications - 47
Citations - 470
Michael Altenbuchinger is an academic researcher from University of Regensburg. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 33 publications receiving 301 citations. Previous affiliations of Michael Altenbuchinger include Harvard University & University of Hohenheim.
Papers
More filters
Journal ArticleDOI
Scattering lengths of Nambu-Goldstone bosons off $D$ mesons and dynamically generated heavy-light mesons
TL;DR: In this paper, a new renormalization scheme is proposed which manifestly satisfies chiral power counting rules and has well-defined behavior in the infinite heavy-quark mass limit.
Journal ArticleDOI
Reference point insensitive molecular data analysis.
Michael Altenbuchinger,Thorsten Rehberg,Helena U. Zacharias,Frank Stämmler,Katja Dettmer,Daniela Weber,Andreas Hiergeist,André Gessner,Ernst Holler,Peter J. Oefner,Rainer Spang +10 more
TL;DR: It is shown that reference point discrepancies compromise the performance of regression models like the LASSO, and zero-sum regression is superior to the LassO in case of a poor choice of reference point both in simulations and in an application that integrates intestinal microbiome analysis with metabolomics.
Journal ArticleDOI
Statistical Analysis of NMR Metabolic Fingerprints: Established Methods and Recent Advances.
TL;DR: A recent development in statistical data analysis, called zero-sum regression, builds metabolite signatures whose estimation as well as predictions are independent of prior normalization, where data normalization becomes obsolete.
Journal ArticleDOI
Gaussian and Mixed Graphical Models as (multi-)omics data analysis tools.
TL;DR: The theoretical foundations of Gaussian Graphical Models are provided, extensions such as MGMs or multi-class GGMs are presented, and how those methods can provide insight in biological mechanisms are illustrated.
Journal ArticleDOI
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Annette M. Staiger,Annette M. Staiger,Michael Altenbuchinger,Marita Ziepert,Christian W. Kohler,Heike Horn,Michael Huttner,Katrin Hüttl,Gunther Glehr,Wolfram Klapper,Monika Szczepanowski,Julia Richter,Harald Stein,Alfred C. Feller,Peter Möller,Martin-Leo Hansmann,Viola Poeschel,Gerhard Held,Markus Loeffler,Norbert Schmitz,Lorenz Trümper,Tobias Pukrop,Andreas Rosenwald,German Ott,Rainer Spang,Emed Demonstrator +25 more
TL;DR: A lymphoma-associated macrophage interaction signature interrogating features of the microenvironment using a NanoString assay applicable to FFPE is constructed and combined analysis of stromal features, the IPI and DE may provide a new rationale for targeted therapy.